AQIX® Fluid Technology.
The World's Only Synthetic Human Interstitial Fluid
Aqix Limited is awarded a Research and Development Grant from the Technology Strategy Board for intravenous application of AQIX® RS-I.
Aqix Limited patent for the intravenous application of AQIX® RS-I is granted in South Africa.
Aqix Limited is to participate as an SME member of the Consortium on Organ Preservation in Europe (COPE) grant award for €5.9M during 2013-17 to provide AQIX® RS-I as the base solution in the quest for improved, normothermic graft preservation of human donor organs.
Aqix Limited receives a notification of intent from the European Patent Office to be granted a EU patent filed in July, 2008, for applications of AQIX® RS-I involving blood/body fluid volume replacement therapies.
European Patent Office grants Aqix Ltd a EU patent for intravenous applications of AQIX® RS-I involving blood/body fluid volume replacement therapies.